The SARS-CoV-2 variant is rapidly spreading across the world and causes to resurge infections. We previously reported that CT-P59 presented its in vivo potency against Beta variants, despite its reduced activity in cell experiments. Yet, it remains uncertain to exert the antiviral effect of CT-P59 on Gamma, Delta and its associated variants (L452R). To tackle this question, we carried out cell tests and animal studies. CT-P59 showed neutralization against Gamma, Delta, Epsilon, and Kappa variants in cells, with reduced susceptibility. The mouse challenge experiments with Gamma and Delta variants substantiated in vivo potency of CT-P59 showing symptom remission and virus abrogation in the respiratory tract. Collectively, cell and animal studies showed that CT-P59 is effective against Gamma and Delta variants infection, hinting that CT-P59 has therapeutic potential for patients infected with Gamma, Delta and its associated variants.

SARS-CoV-2 变种正在世界范围内迅速传播并导致感染卷土重来。我们之前报道过，尽管 CT-P59在细胞实验中的活性降低，但它在体内表现出了针对 Beta 变体的效力。然而，CT-P59 对 Gamma、Delta 及其相关变体 (L452R) 的抗病毒作用仍不确定。为了解决这个问题，我们进行了细胞测试和动物研究。CT-P59 显示出对细胞中 Gamma、Delta、Epsilon 和 Kappa 变体的中和作用，且易感性降低。Gamma 和 Delta 变体的小鼠攻击实验在体内得到证实CT-P59 的效力显示呼吸道症状缓解和病毒消除。总的来说，细胞和动物研究表明 CT-P59 对 Gamma 和 Delta 变体感染有效，暗示 CT-P59 对感染 Gamma、Delta 及其相关变体的患者具有治疗潜力。